in the EU for use in combination with other antiretroviral medicinal products for treatment-experienced adult patients with only CCR5-tropic HIV-1 detectable.

  Late-stage clinical trials for additional uses and dosage forms for in-line products:

  PRODUCT INDICATION

Celebrex     Acute gouty arthritis

  Eraxis/Vfend Combination Aspergillosis fungal infections

  Lyrica Epilepsy monotherapy; post-operative pain; restless legs syndrome; central neuropathic pain due to spinal cord injury; peripheral neuropathic pain

Macugen     Diabetic macular edema

  Prevnar/Prevenar 13 Adult Prevention of invasive pneumococcal disease in adults

Revatio     Pediatric pulmonary arterial hypertension

Sutent     Breast cancer; non-small cell lung cancer; prostate cancer; liver cancer

  Zithromax/chloroquine Malaria

In early 2009, we had four Phase 3 studies evaluating Sutent for the treatment of advanced breast cancer. In March 2009, we discontinued a Phase 3 trial of single-agent Sutent versus Xeloda (capecitabine) for treatment of advanced breast cancer. In June 2009, we discontinued another Phase 3 trial that compared Sutent plus Taxol (paclitaxel) to Avastin (bevacizumab) plus Taxol for first-line treatment of advanced breast cancer. Both studies were discontinued due to futility. We continue to study Sutent for treatment of advanced breast cancer in two other Phase 3 trials, which have completed enrollment. In June 2009, we discontinued a Phase 3 trial of Sutent for first-line treatment of metastatic colorectal cancer due to futility.

 New drug candidates in late-stage development in the U.S.:

CANDIDATE     INDICATION

  Apixaban For acute coronary syndrome, the prevention and treatment of venous thromboembolism and prevention of stroke in patients with atrial fibrillation, which is being developed in collaboration with

BMS

Axitinib     A multi-targeted kinase inhibitor for the treatment of renal cell carcinoma

  Bapineuzumab A beta amyloid inhibitor for the treatment of Alzheimer’s disease being developed in collaboration with Janssen Alzheimer Immunotherapy Research & Development, LLC, a subsidiary of Johnson

& Johnson

  Bazedoxifene-conjugated A tissue selective estrogen complex for the treatment of menopausal vasomotor symptoms estrogens (Aprela)

Bosutinib     An src kinase inhibitor for the treatment of chronic myelogenous leukemia

  Figitumumab (CP-751871) An anti-insulin-like growth factor receptor 1 (IGF1R) human monoclonal antibody for the treatment of non-small cell lung cancer

  Latrepirdine (Dimebon) A novel mitochondrial protectant and enhancer being developed in partnership with Medivation for the treatment of Alzheimer’s disease and Huntington’s disease

Moxidectin     Treatment of onchocerciasis (river blindness)

Neratinib     A pan-HER inhibitor for the treatment of breast cancer

  PF-02341066 An oral c-Met and ALK inhibitor for the treatment of advanced non-small cell lung cancer

PF-0299804     A pan-HER tyrosine kinase inhibitor for the treatment of lung cancer

Tanezumab     An anti-nerve growth factor monoclonal antibody for the treatment of pain

  Tasocitinib (CP-690,550) A JAK-3 kinase inhibitor for the